Mazindol is a centrally acting sympathomimetic anorectic compound that has been used as an appetite suppressant in the management of obesity. It belongs to the stimulant/anorectic class and acts primarily through modulation of central monoaminergic neurotransmission.
Mazindol has been investigated and used in certain countries as an adjunct to calorie-restricted diet and lifestyle modification for weight management. Its pharmacological activity is associated with effects on appetite and central nervous system neurotransmitter pathways.
Mazindol is a synthetic tricyclic imidazoline derivative with the molecular formula C16H13ClN2O and a molecular weight of approximately 284.74 g/mol. Its CAS Number is 22232-71-9.
Mazindol is supplied as a pharmaceutical-grade active pharmaceutical ingredient for qualified pharmaceutical formulation and research applications.
Mazindol produces anorectic activity through effects on central monoamine neurotransmission, including inhibition of norepinephrine and dopamine reuptake.
Increased availability of these neurotransmitters in relevant central nervous system pathways contributes to appetite suppression and reduced food intake.
Mazindol has been used as an anorectic agent for weight management in combination with dietary and lifestyle measures.
Its regulatory status and approved indications may differ between countries, so applicable local regulatory requirements should be verified before pharmaceutical use or commercialization.
Mazindol API can be evaluated using validated analytical methods for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
HPLC and spectroscopic techniques may be used for identity, assay and purity testing. Appropriate controls should be established for process-related impurities, degradation products and residual solvents.
Final acceptance criteria should be based on the applicable manufacturer's approved drug-substance specification and Certificate of Analysis.
Mazindol should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. It should be protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Mazindol API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Mazindol API is available for qualified pharmaceutical development and manufacturing requirements. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 4.0 – 6.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |